Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Ibrutinib

2

XVII.a Respiratory tract infection incl. pneumonia

2
Last update : 15/10/2016
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
The Lancet. Oncology 2016 Oct;17;1409-1418 2016 Oct
Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.
Bone marrow transplantation 2016 Jun;51;793-8 2016 Jun
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Blood 2015 Aug 06;126;739-45 2015 Aug 06

Powered by

  • ^
  • Contact
  • Cookies
  • About